ACADIA Pharmaceuticals has released data on NUPLAZID, a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. This treatment is meant to treat Parkinson's disease patients, specifically the delusions…
Medical professionals are still trying to understand all of the underlying causes of Parkinson's disease, a progressive disease that sees the degeneration and death of motor neurons. A recent study…
Over 50 years ago, levodopa was approved to treat patients with Parkinson's disease. To this day, levodopa, administered via pills or intravenously, remains the standard-of-care. But according to Parkinson's News…
According to a story from Parkinson's News Today, a small study recently demonstrated that fecal transplants could help relieve gastrointestinal problems in Parkinson's disease patients, as well as reducing the…
Have you ever thought about whether measuring caffeine levels could give you insight into disease progression? Well according to Parkinson's News Today, researchers have discovered a potential link between…
There are many rare diseases that are not yet fully understood, with Parkinson's disease being one of them. Medical professionals have discovered a lot about the underlying causes of the…
Did you know that an estimated 30% of patients with Parkinson's disease (PD) experience diplopia (double vision)? According to Parkinson's News Today, a large longitudinal study determined that diplopia is…
The 2021 virtual American Academy of Neurology (AAN) Annual Meeting is taking place from April 17 through April 22, 2021. During the conference, experts and researchers are offering a…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
